SIGA Technologies, Inc. (SIGA) stock analysis

Healthcare · Drug Manufacturers - Specialty & Generic

From the 10-K filed 2026-03-10

How it makes money

It earns by selling antiviral drugs to government stockpiles, where contract renewals and the size of government-ordered volumes dictate its financial results.

It relies on government agencies, primarily the U.S. government, to purchase its flagship drug, TPOXX, to maintain national stockpiles for public health emergencies like smallpox. Revenue is driven by the timing and size of these procurement contracts rather than traditional commercial market demand. Profitability depends on the company's ability to win contract renewals and ensure the government continues to exercise options for additional supplies.

What protects it: the moat

It relies on regulatory approvals and government-specific procurement hurdles that act as barriers to entry for potential generic or alternative competitors.

The company benefits from regulatory authorizations granted under 'exceptional circumstances' due to the rarity of the diseases it treats, which complicates clinical study feasibility for others. Management claims that the specialized nature of its biodefense products and its entrenched status within established government supply chains provide a competitive moat, though its primary protection is the nature of government contracts.

What growth costs

It incurs ongoing costs for clinical trials and regulatory compliance, but the filing provides no specific disclosure regarding future capital expenditure requirements.

To maintain its regulatory approvals and pursue new indications, such as post-exposure prophylaxis, it must fund continuous clinical data collection and safety monitoring. The filing does not disclose specific capital expenditure figures, though it notes that managing a domestic supply chain for active pharmaceutical ingredients requires resources to mitigate potential macroeconomic volatility.

What could damage it

The loss of government procurement contracts, caused by shifting political priorities or budgetary constraints, would permanently impair its ability to generate revenue.

Because its business model is nearly entirely dependent on a single category of customer—government agencies—the failure to secure future contracts or the non-exercise of existing contract options would remove the primary source of cash flow. This concentration means there is no diversified commercial market to offset a government decision to stop stockpiling its product.

About SIGA Technologies, Inc.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.

Other companies in Drug Manufacturers - Specialty & Generic